Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Study Estimates Cost Added To Private Health Insurance Premiums To Cover Uncompensated Care
The average U.S. family and their employers paid an additional $1,017 in health care premiums in 2008 to pay for care of the uninsured, according to a study released on Thursday by Families USA, USA Today reports (Kim, USA Today, 5/28). According to the study, which examined federal data, the uninsured received $116 billion in health care from hospitals, physicians and other providers in 2008 and paid 37% of that amount. Government programs and charities covered an additional 26%, which left another 37%, or about $43 billion, unpaid. The study then estimated how those costs are when spread across the insured through higher premiums, the study found. According to the study, prepared by the actuarial firm Milliman, the average additional amount paid under private coverage for single individuals was about $370 per year (Werner, AP/Austin American-Statesman, 5/28). Families USA Executive Director Ron Pollack said, "This is a hidden tax on all insurance premiums, whether it is paid by business for their work or by families when they purchase their own coverage" (USA Today, 5/28).The study is available online.
generic viagra online
CEL-SCI Files Patent Application To Support Company's Treatment For More Virulent Strain Of H1N1 Swine And Other Influenza Viruses
CEL-SCI CORPORATION (NYSE AMEX: CVM) announced that it has filed a provisional U.S. patent application covering its L.E.A.P.S.(TM) immune therapy drugs (vaccines) for the prevention/treatment of H1N1, swine, bird flu, Influenza A and/or evolving mutants or variants of these viruses. Some experts believe that by the next flu season the swine flu virus will have evolved and/or combined with other viruses to create a much more lethal new virus. That is what happened in the case of the Spanish flu pandemic. CEL-SCI"s efforts to fight this virus are focused on using conserved epitopes from essential proteins to be found in the A influenza virus for H1N1, H1N5, swine, bird flu and Spanish influenza to create an effective vaccine/treatment that could potentially fight such a mutant virus. Drugshop to buy zoloft online and other pills.
News of the day
Doctors Diagnosing Bipolar Disorder In Children Should Consider Irritability A Symptom, Study
New research from the US adds to mounting evidence that when diagnosing bipolar disorder in children doctors and clinicians should consider
Cardiovascular

Sirona Biochem Starts Testing First Batch Of Drug Candidates Designed To Combat Diabetes And Obesity

Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on diabetes and obesity, announced today that it has now taken delivery of its first batch of unique SGLT compounds from its French partner TFChem (Rouen, France) for screening and evaluation. "The successful production of these new molecules marks a significant company milestone," said CEO, Dr. Howard Verrico. Sirona Biochem owns the worldwide product rights to a library of sodium glucose transporter (SGLT) inhibitors to treat diabetes and obesity. SGLT Inhibitors block the reuptake of excess sugars from urine in the kidney which can then reduce high blood sugar to normal levels. It"s estimated that there are nearly 21 million people in the United States, or 7% of the population, who are diabetic. About 15 million have been diagnosed with the disease, but over 6 million people are unaware that they are suffering from it. It is forecast that by 2025, 333 million people will have diabetes. Management of sugar metabolism is a primary medical challenge associated with treating diabetes and obesity. Dr. Verrico explained that, "As far as we have been able to verify, these are a truly unique group of SGLT inhibitors in the world. To our knowledge, TFChem is the first to synthesize these uniquely designed molecules. SGLT inhibitors are a new and exciting class of compounds that have great promise for the treatment of diabetes and obesity. "This new drug class is one considered to have substantial market potential in the fight against diabetes and obesity, particularly if we can prove our versions to be robust enough to survive the journey through the body and result in reduced blood sugar levels. "The test results will then enable us, through ongoing refinement of molecular development, to identify our lead compounds for in vivo testing projected to start early next year," concluded Dr. Verrico. The tests were developed by SignalChem (Richmond, BC). Sirona"s scientific team aims to identify lead compounds by the end of 2009. Sirona Biochem"s website is at -- http://www.sironabiochem.com -- where we feature the most recent information about the company and its activities. Alternatively, investors are able to e-mail all questions and correspondence to info@sironabiochem.com where they can also request to be added to the investor e-mail list to receive all future press releases and updates or call John Dougherty, Corporate Development at 604-641-4466. About Sirona Biochem Sirona Biochem Corp. (TSX-V: SBM) is an emerging biotech company dedicated to the discovery and development of novel drug compounds. The current focus is on treatments for Type II Diabetes and Obesity. Sirona has entered into a license agreement with TFChem S.A.R.L., a Drug Discovery company based in Rouen, France. TFChem licenses its technology of fluorinated carbohydrate mimics: GlycoMim®, and products in development to biotech companies. The license agreement with TFChem provides for research and development of new compounds known as SGLT Inhibitors. SGLT inhibitors are a new and exciting class of compounds that have great promise and potential to treat both diabetes and obesity. http://www.sironabiochem.com. About TFChemistry TFChem, of Rouen, France, is a drug-discovery company which uses fluorine atom properties to develop new glycomimetic compounds: the GlycoMim® technology. TFChem is a leader in the area of fluorinated glycosides and their application as new, more potent and safer drugs. Through application of the patented core technology it is the intention to modify and discover new carbohydrate based drug compounds with increased therapeutic properties and clinical improvement potential. Sirona Biochem


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009